Source-grounded facts extracted from ZyVersa Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ZyVersa Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $1 million (effective 2026-02-27).
“On February 27, 2026, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company issued and sold to the Purchasers convertible promissory notes in an aggregate principal amount of $1 million (the “Notes”) and Series A-4 Common Stock Purchase Warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).”
Listing & Compliance Notices
ZyVersa Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“dicating that the Panel had determined to delist the Company’s securities from Nasdaq and that trading in the Company’s securities would be suspended at the open of trading on July 17, 2025, due to the Company’s failure to regain compliance with the minimum bid price requirements under Listing Rule 5550(a)(2) . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of hi”
Listing & Compliance Notices
ZyVersa Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“July 15, 2025, ZyVersa Therapeutics, Inc. (the “Company”) received a determination letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to deny the Company’s request to continue its listing on The Nasdaq Capital Market. As previously disclosed, the Nasdaq Listing Qualifications Department (the “Staff”) notified the Company of its determination to delist the Company’s securities because the Company is not in compliance with the minimum bid price requirements under Listing Rule 5550(a)(2), unless the Company requ”
Governance Changes
ZyVersa Therapeutics, Inc.: Filed a certificate of amendment to effect a 1-for-10 reverse stock split of common stock (effective 2024-04-25).
“On April 25, 2024, ZyVersa Therapeutics, Inc. (the "Company") filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware relating to a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”). The Reverse Stock Split became effective on April 25, 2024 at 4:01 p.m., and the Common Stock is expected to begin trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on April 26, 2024 at market open.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.